Shares of Marrone Bio Innovations Inc (NASDAQ:MBII) have been given a consensus rating of “Hold” by the six analysts that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $2.35.

Several research firms have commented on MBII. Zacks Investment Research downgraded shares of Marrone Bio Innovations from a “hold” rating to a “sell” rating in a report on Thursday, November 29th. National Securities reiterated a “buy” rating and issued a $2.50 price objective on shares of Marrone Bio Innovations in a report on Friday.

NASDAQ:MBII opened at $1.65 on Thursday. Marrone Bio Innovations has a one year low of $1.10 and a one year high of $3.39. The firm has a market capitalization of $182.64 million, a price-to-earnings ratio of -1.54 and a beta of -0.14. The company has a debt-to-equity ratio of 1.06, a quick ratio of 2.52 and a current ratio of 3.42.

In other Marrone Bio Innovations news, major shareholder Van Herk Investments B.V. sold 1,500,000 shares of the company’s stock in a transaction on Thursday, February 21st. The shares were sold at an average price of $1.57, for a total value of $2,355,000.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 2.90% of the stock is owned by insiders.

Several hedge funds have recently added to or reduced their stakes in MBII. Paloma Partners Management Co acquired a new position in shares of Marrone Bio Innovations in the fourth quarter valued at about $73,000. Rhumbline Advisers grew its stake in shares of Marrone Bio Innovations by 44.3% in the fourth quarter. Rhumbline Advisers now owns 68,021 shares of the basic materials company’s stock valued at $100,000 after acquiring an additional 20,882 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Marrone Bio Innovations by 5.8% in the fourth quarter. Geode Capital Management LLC now owns 443,611 shares of the basic materials company’s stock valued at $652,000 after acquiring an additional 24,460 shares in the last quarter. Northern Trust Corp grew its stake in Marrone Bio Innovations by 1,503.9% during the second quarter. Northern Trust Corp now owns 512,232 shares of the basic materials company’s stock worth $943,000 after buying an additional 480,296 shares in the last quarter. Finally, BlackRock Inc. grew its stake in Marrone Bio Innovations by 0.5% during the fourth quarter. BlackRock Inc. now owns 2,800,519 shares of the basic materials company’s stock worth $4,117,000 after buying an additional 14,014 shares in the last quarter. Institutional investors and hedge funds own 42.07% of the company’s stock.

About Marrone Bio Innovations

Marrone Bio Innovations, Inc provides bio-based pest management and plant health products primarily for agricultural and water markets in the United States and internationally. It offers herbicides; fungicides; nematicides; insecticides; algaecides for algae control; molluscicides for mussel and snail control; plant growth and stress regulators; and water treatment products for various applications, such as hydroelectric and thermoelectric power generation, industrial applications, drinking water, aquaculture, irrigation, and recreation.

Read More: How Do Front-End Loads Impact an Investment?

Receive News & Ratings for Marrone Bio Innovations Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marrone Bio Innovations and related companies with MarketBeat.com's FREE daily email newsletter.